Association of CYP2C19 gene single nucleotide polymorphisms (rs12248560 and rs4244285) with response to thalidomide in transfusion dependent β-thalassemia patients- a 12-months follow-up study [0.03%]
CYP2C19基因单核苷酸多态性（rs12248560和rs4244285）与输血依赖型β-地中海贫血患者反应木尼丁疗效的关联：一项为期一年的随访研究
Inayat Ur Rahman,Muhammad Shahid,Muhammad Tariq Humayun Khan et al.
Inayat Ur Rahman et al.
Aim: This study aimed to evaluate the efficacy of thalidomide in transfusion-dependent β-thalassemia (TDT) patients and explore its association with CYP2C19 polymorphisms (rs12248560 and rs4244285). ...
M Eileen Dolan
M Eileen Dolan
ATP-binding cassette transporter polymorphisms and the pharmacokinetics of oral esketamine [0.03%]
ABCB转运体多态性与口服艾斯氯胺酮药代动力学的关系
Jerome Oude Nijhuis,Daniël Coerts,Jens van Dalfsen et al.
Jerome Oude Nijhuis et al.
Oral esketamine is a promising new therapy for treatment-resistant depression. However, concerns exist about interindividual pharmacokinetic variability. Genetic polymorphisms regulating the expression of ATP-binding cassette (ABC) transpor...
Correction [0.03%]
改正
Published Erratum
Pharmacogenomics. 2026 Jan 20:1. DOI:10.1080/14622416.2026.2619352 2026
A review of the existing pharmacogenomic literature of naltrexone for use in alcohol use disorder [0.03%]
纳曲酮治疗酒精使用障碍的药理基因组学文献综述
Christopher Counts,Nisha Ali,Syed Ali et al.
Christopher Counts et al.
Naltrexone is an opioid receptor antagonist used to treat alcohol use disorder; however, like other commonly used addiction treatment options, it demonstrates inconsistency in treatment response. Pharmacogenomics may be used to individualiz...
Dihydropyrimidine dehydrogenase testing: capturing what standard genotyping misses with next-generation sequencing [0.03%]
二氢嘧啶脱氢酶检测：通过下一代测序技术弥补标准基因分型的不足
Maxime Sourdioux,Mohamed Ksentini,Dorian Chastagner et al.
Maxime Sourdioux et al.
Background: Screening for dihydropyrimidine dehydrogenase (DPD) deficiency has been recommended by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) to prevent fluoropyrimidine toxic...
Pharmacogenomic testing for Prader-Willi syndrome: a mixed methods analysis of caregiver experiences and utilization [0.03%]
普瑞德-威利综合征的药物基因组检测：基于护理者经历和使用的混合研究分析
Anna Carpenter Harris,Jessica J Denton,Yael Bar-Peled et al.
Anna Carpenter Harris et al.
Aim: This study aims to better understand the utility of pharmacogenomic (PGx) testing for the rare disease, Prader-Willi syndrome (PWS). Methods: ...
Patient and provider perceptions of pharmacogenetic testing in gynecologic surgery: a cross-sectional analysis [0.03%]
妇科手术患者和提供者对药物基因组学检测的感知：横断面分析
Glenda Hoffecker,Victoria Wittner,Lakeisha Mulugeta-Gordon et al.
Glenda Hoffecker et al.
Aim: To determine Penn Medicine patients' and gynecologic providers' knowledge and attitudes about pharmacogenetic (PGx) testing. Methods: ...
Clinically actionable genetic variation in patients with or at high-risk of cardiovascular diseases from the Montreal Heart Institute [0.03%]
蒙特利尔心脏研究所心血管疾病患者或高危人群的可临床操作的基因变异
Marc-Olivier Pilon,Jessica Hindi,Essaïd Oussaïd et al.
Marc-Olivier Pilon et al.
Aim: Pharmacogenomics enables treatments to be tailored to individual genetic profiles, optimizing efficacy while reducing adverse effects. The Clinical Pharmacogenetics Implementation Consortium (CPIC) classifies gene-dr...
Association between ABCG2 polymorphisms and allopurinol response in gout patients: a systematic review and meta-analysis [0.03%]
ABCG2多态性与痛风患者别嘌醇反应性的关联：系统评价和meta分析
Jia Wen Lee,Muhammad Danish Badrul Hisham,Xin Yee Low et al.
Jia Wen Lee et al.
Aim: This systematic review and meta-analysis aimed to investigate the association between ABCG2 polymorphisms and allopurinol response in gout patients. ...